Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Scientists discovered a way to block hepatitis B infection using an anticancer drug, offering hope for new treatments.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

Hepatitis B can lead to liver disease. But we can prevent and manage this viral infection. Here’s what we know about the ...

The data included results from a Phase 3 study on Biktarvy’s efficacy in treating HIV and HBV co-infection, a Phase 2 study on a long-acting treatment regimen, and findings from the first HIV ...

Chronic hepatitis B (CHB) remains a major global health challenge, with functional cure achieved in only a small subset of patients. Current oral antiviral agents effectively suppress viral ...

To facilitate the achieving of the goal of “eliminating viral hepatitis as a major public health threat by 2030” set by the World Health Organization, the Chinese Society of Hepatology together with ...

The American Gastroenterological Association (AGA) has released an updated clinical practice guideline on the prevention of ...

The data included results from a Phase 3 study on Biktarvy’s efficacy in treating HIV and HBV co-infection, a Phase 2 study on a long-acting treatment regimen, and findings from the first HIV cure ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...